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ABSTRACT 
Background and Objectives: The antihypertensive efficacy and tolerability of losartan (LST) in fixed combination 
with hydrochlorothiazide (HCTZ) has not been compared to those of amlodipine monotherapy in Asians. This is 
an important comparison to draw, because Asians have been suggested to respond more favorably to calcium 
channel blockers and less favorably to angiotensin-converting enzyme inhibitors in comparison to Westerners. 
We sought to compare these two regimens in Korean patients with mild to moderate hypertension. Subjects and 
Methods: 174 patients were randomized to receive LST 50 mg once daily, which could be titrated to LST/HCTZ 
50/12.5 mg at 4 weeks, followed by 100/25 mg at 8 weeks; or to receive amlodipine besylate 2.5 mg once daily, 
which could be titrated to 5 mg at 4 weeks, followed by 10 mg at 8 weeks to achieve diastolic blood pressure <90 
mmHg. Results: At 12 weeks, the differences between the LST/HCTZ and amlodipine groups with regard to 
diastolic and systolic blood pressure were 1.2 mmHg (95% confidence interval: -1.1 to 3.4) and -0.5 mmHg (95% 
confidence interval: -4.3 to 3.4), respectively. The rates of achieving systolic blood pressure <140 mmHg were 
66.7% in the LST/HCTZ group and 75.9% in the amlodipine group (p=0.20). The rates of drug-related adverse 
events were 15.6% in the LST/HCTZ group and 11.9% in the amlodipine group (p=0.49). Conclusion: The two 
regimens, with a relatively higher dose of LST/HCTZ compared to that required in Westerners, produced equi-
valent blood pressure reduction and were comparably well tolerated in Korean patients with mild to moderate 
hypertension. (Korean Circ J 2009;39:151-156) 
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Introduction 
 
In most hypertensive patients, two or more drugs are 
required to achieve target blood pressure goals.
1) In this 
respect, combinations of two drugs in a single tablet (i.e., 
fixed combinations) carry the advantages of increased 
compliance and cost-effectiveness.
2)3) Thus, their market 
share is rapidly increasing. Among the various fixed 
combinations of antihypertensive drugs, those of an-
giotensin II receptor blockers (ARBs) and hydrochlo-
rothiazide (HCTZ) are most widely used because of their 
synergism in antihypertensive efficacy, as well as their 
counterbalance of side effects.
4)5) 
There have been several studies comparing the anti-
hypertensive efficacy and tolerability of a fixed com-
bination of losartan (LST) (the first of the ARBs) and 
HCTZ with those of amlodipine besylate in Wester-
ners.
6-9) However, these is little data in Asians, who have 
been suggested to respond more favorably to calcium 
channel blockers and less favorably to angiotensin-con-
verting enzyme inhibitors compared to Westerners.
10) 
In this study, we compared the antihypertensive efficacy 
and tolerability of a fixed combination of LST and HC-
TZ with those of amlodipine besylate monotherapy in 
Korean patients with mild to moderate hypertension. 
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Subjects and Methods 
 
Patients and study design 
This study was performed with a multi-centre, ran-
domized, open-label, parallel-group design at six sites 
in the Republic of Korea. The study protocol was re-
viewed and approved by the institutional review board 
at each site. 
The study consisted of initial screening, a 2-week 
washout period, and a 12-week active treatment period. 
Outpatients from 20 to 75 years of age with uncompli-
cated, essential hypertension were eligible for the study. 
All patients delivered informed consent before enter-
ing the study. Complete medical history, physical exami-
nation, and laboratory tests were evaluated during the 
initial screening. 
After the 2-week washout period, patients whose base-
line sitting diastolic blood pressure (SiDBP) was be-
tween 90 and 114 mmHg were randomized to receive 
either LST 50 mg once daily for the LST/HCTZ group 
or amlodipine besylate 2.5 mg once daily for the amlo-
dipine group. To achieve SiDBP <90 mmHg, regimens 
could be titrated to LST/HCTZ 50/12.5 mg at 4 weeks, 
followed by 100/25 mg at 8 weeks in the LST/HCTZ 
group. Similarly, in the amlodipine group, amlodipine 
besylate could be titrated to 5 mg at 4 weeks followed 
by 10 mg at 8 weeks. The treatment schedule is sum-
marized in Fig. 1. 
At each visit, sitting systolic blood pressure (SiSBP), 
SiDBP, and pulse rate were measured. Blood pressure 
was measured at the same time of the day, before dosing, 
in the same arm, and by the same investigator, at each 
center, with mercury sphygmomanometers manufac-
tured by one company (W. A. Baum Co. Inc, New York, 
U.S.A.).
11) At each visit, patients were asked about ad-
verse events (AEs). 
Efficacy and safety variables 
The primary efficacy variable was the difference in 
the mean change of SiDBP between the two groups at 
12 weeks. The secondary efficacy variables included 
the difference in the mean change of SiSBP; the mean 
change of SiDBP, SiSBP, and pulse rates; and the res-
ponse rate defined as the proportion of patients whose 
SiSBP was <140 mmHg at 12 weeks. 
Tolerability was assessed based on the incidence of 
overall (reported by the patients) or drug-related (ad-
judicated by the investigators) AEs, expressed as the 
proportion of patients reporting one or more AEs. The 
mean change in laboratory measures at 12 weeks was 
also assessed, including serum uric acid levels. 
 
Statistical analysis 
For the comparison of the two groups, the prespecif-
ied boundary for non-difference in the mean change 
of SiDBP was defined as [-6, 6] mmHg. Assuming the 
between-group difference in the mean change of SiDBP 
as 6.0 mmHg, with a standard deviation of 10 mmHg 
and an exclusion rate of 30%, we calculated that 88 
patients per treatment group would provide 90% power 
to detect a statistically significant difference with a 2-
sided α  level of 0.05. Efficacy variables were compared 
using the analysis of covariance test. The pattern of serial 
changes in blood pressure through 4, 8, and 12 weeks 
was compared using the repeated measures analysis of 
variance test. 
The efficacy measures were analyzed in two popula-
tions. The intention-to-treat (ITT) population included 
the patients who had received at least 1 dose of the 
study drug after randomization, had valid baseline data, 
and had at least 1 valid post-baseline data. On ITT an-
alysis, any missing post-randomization measures were 
estimated by carrying forward the last observed data. 
The per-protocol (PP) population included only those 
patients who had completed the 12-week treatment sc-
hedule and whose drug compliance was 75% or better. 
Tolerability measures were analyzed in the ITT popu-
lation, which included all patients who took at least 1 
dose of the study drug. The incidence of AEs was com-
pared between the two groups using the chi-square or 
Fisher’s exact test, where appropriate. 
 
Results 
 
Patients 
After the 2-week washout period, 176 patients were 
randomly assigned to the LST/HCTZ group (n=90) 
or the amlodipine group (n=84). The baseline charac-
teristics of the two groups are summarized in Table 1. 
During the active treatment period, 11 patients (12.2%) 
in the LST/HCTZ group and 11 patients (13.1%) in the 
amlodipine group dropped out of the study. At 12 weeks, 
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Fig. 1. The treatment schedules for the losartan/hydrochloro-
thiazide group and the amlodipine group. After a 2-week washout
period, eligible patients were randomized to receive losartan 50
mg once daily or amlodipine besylate 2.5 mg once daily. Doses
were titrated at 4 weeks and 8 weeks to achieve a diastolic blood
pressure of <90 mmHg. WO: washout period, L: losartan, H: hy-
drochlorothiazide, A: amlodipine besylate.  
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46 (58.2%), 19 (24.1%), and 14 (17.7%) patients in the 
LST/HCTZ group were treated with LST 50 mg, LST/ 
HCTZ 50/12.5 mg, and 100/25 mg, respectively. In 
the amlodipine group, 33 (45.2%), 28 (38.4%), and 12 
(16.4%) patients were treated with amlodipine besylate 
2.5 mg, 5 mg, and 10 mg, respectively. Fig. 2 depicts 
the dose titration status of the two groups at 12 weeks. 
Drug compliance was comparable between the two treat-
ment groups.   
The number of patients whose drug compliance was 
75% or better was 77 (85.6%) in the LST/HCTZ group 
and 72 (85.7%) in the amlodipine group. 
 
Changes in sitting diastolic blood pressure 
In the ITT population (n=160), SiDBP was signifi-
cantly reduced at 12 weeks by 11.6 mmHg {95% con-
fidence interval (CI): 10.1 to 13.2} in the LST/HCTZ 
group and by 12.8 mmHg (95% CI: 11.2 to 14.4) in the 
amlodipine group (p<0.001 for both groups). However, 
the difference in the mean change of SiDBP between 
the two groups was not significant between the two 
groups {1.2 mmHg (95% CI: -1.1 to 3.4), p=0.31}. In 
the PP population (n=137), SiDBP was also signifi-
cantly reduced at 12 weeks by 1 1.7 mmHg (95% CI: 
10.0 to 13.4) in the LST/HCTZ group and by 12.9 
mmHg (95% CI: 11.2 to 14.5) in the amlodipine group 
(p<0.001 for both groups).  
However, the difference in the mean change of SiDBP 
between the two groups was not significant {1.1 mmHg 
(95% CI: -1.3 to 3.5), p=0.35}. These results are sum-
marized in Table 2. 
 
Changes in sitting systolic blood pressure 
In the ITT population, SiSBP was significantly re-
duced at 12 weeks by 19.7 mmHg (95% CI: 17.0 to 
22.4) in  t h e  L S T/ HC TZ g r o u p an d  b y  1 9 .2  m mHg  
(95% CI: 16.5 to 21.9) in the amlodipine group (p< 
0.001 for both groups). However, the difference in the 
mean change of SiSBP between the two groups was not 
significant {-0.5 mmHg (95% CI: -4.3 to 3.4), p=0.82}. 
In the PP population, SiSBP was also significantly re-
duced at 12 weeks by 20.4 mmHg (95% CI: 17.6 to 
23.2) in the LST/HCTZ group and by 19.9 mmHg 
(95% CI: 17.1 to 22.6) in the amlodipine group (p< 
0.001 for both groups). However, the difference in the 
mean change of SiSBP between the two groups was not 
significant {-0.5 mmHg (95% CI: -4.5 to 3.4), p=0.79}. 
These results are summarized in Table 3.   
There was no significant difference in the response 
rates for the LST/HCTZ group (66.7%) and the amlo-
dipine group (75.9%) (p=0.20). 
Table 1. Baseline characteristics of randomized patients
  LST/HCTZ group 
(n=90) 
Amlodipine group 
(n=84) 
Male, n (%)  51 (56.7)  51 (60.7) 
Age (years)  54.3±9.1 54.2±8.7 
SiSBP (mmHg)  155.1±12.8 151.7±11.6 
SiDBP (mmHg)  99.1±6.3 98.6±6.6 
Pulse rate (beats/minute)  68.4±7.6 71.8±9.3 
Weight (kg)  66.7±10.2 67.5±11.2 
Height (cm)  164.0±7.7 164.7±8.9 
Continuous variables are expressed as means±standard deviation.
SiSBP: sitting systolic blood pressure, SiDBP: sitting diastolic blood
pressure, LST/HCTZ: losartan/hydrochlorothiazide 
 
Table 2. Effect of losartan-based regimen and amlodipine-based regimen on sitting diastolic blood pressure at 12 weeks 
  LST/HCTZ group  Amlodipine group  Difference*  p 
Intention-to-Treat (n=81) (n=79)    
Baseline (mmHg)  99.3±6.1 98.5±6.6    
Week 12 (mmHg)  87.5±8.4 85.9±7.4    
Change from baseline  -11.6 [-13.2, -10.1]  -12.8 [-14.4, -11.2] 1.2  [-1.1, 3.4]  0.31 
p  <0.001  <0.001    
Per-Protocol (n=68) (n=69)    
Baseline (mmHg)  99.1±5.8 98.3±6.6    
Week 12 (mmHg)  87.3±8.1 85.6±7.7    
Change from baseline  -11.7 [-13.4, -10.0]  -12.9 [-14.5, -11.2] 1.1  [-1.3, 3.5]  0.35 
p  <0.001  <0.001    
All measures are expressed as means±standard deviation, or as least square means (95% confidence interval). *LST/HCTZ group-amlodi-
pine group. LST/HCTZ: losartan/hydrochlorothiazide   
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Serial changes in blood pressure 
Fig. 3 demonstrates the serial changes in blood pres-
sure. SiDBP during the active treatment period showed 
no significant difference between the two groups (p= 
0.17). There were also no significant differences in the 
SiDBP change between the two groups during any of the 
three 4-week intervals (p=0.11, 0.17, and 0.42 for the 
first, second, and third 4-week intervals, respectively). 
The serial changes in SiSBP during the active treat-
ment were not significantly different between the two 
groups (p=0.19). The SiSBP change during the first 4-
week interval was greater in the LST/HCTZ group 
(p=0.04), but was not significantly different during 
the second or third 4-week intervals (p=0.49 and 0.62 
for the second and third 4-week intervals, respectively). 
 
Tolerability 
The overall incidence of AEs was similar between the 
LST/HCTZ group (35.6%) and the amlodipine group 
(34.5%) (p=0.89). The difference in the incidence of 
drug-related AEs was insignificant between the LST/ 
HCTZ group (15.6%) and the amlodipine group (11.9%) 
(p=0.49). The list of AEs considered to be drug-re-
lated is summarized in Table 4. Dizziness and headache 
were the most common AEs in both treatment groups. 
There were no severe AEs requiring special treatment 
or hospitalization. Through the three 4-week intervals, 
there was no significant serial increase in the incidence 
of AEs. The incidences of AEs were 25.6%, 23.3%, and 
27.8% during the first, second, and third 4-week in-
tervals in the LST/HCTZ group, and 21.4%, 23.8%, 
and 13.1% during the respective 4-week intervals in the 
amlodipine group. There were no significant changes 
in pulse rates or laboratory parameters from baseline, 
Table 3. Effect of losartan-based regimen and amlodipine-based regimen on sitting systolic blood pressure at 12 weeks 
  LST/HCTZ group  Amlodipine group  Difference*  p 
Intention-to-Treat (n=81) (n=79)    
Baseline (mmHg)  155.7±13.0 151.5±11.8    
Week 12 (mmHg)  135.2±15.9 133.0±12.6    
Change from baseline  -19.7 [-22.4, -17.0]  -19.2 [-21.9, -16.5]  -0.5 [-4.3, 3.4]  0.82 
p  <0.001  <0.001    
Per-Protocol (n=68) (n=69)    
Baseline (mm Hg)  155.8±12.3 151.4±11.3    
Week 12 (mm Hg)  134.6±14.1 132.4±13.1    
Change from baseline  -20.4 [-23.2, -17.6]  -19.9 [-22.6, -17.1]  -0.5 [-4.5, 3.4]  0.79 
p  <0.001  <0.001    
All measures are expressed as means±standard deviation, or as least square means [95% confidence interval]. *LST/HCTZ group-amlodi-
pine group. LST/HCTZ: losartan/hydrochlorothiazide. 
 
Table 4. Incidence of overall and drug-related adverse events
  LST/HCTZ 
group (n=90) 
Amlodipine 
group (n=84) 
p 
Patients with one or 
more AEs, n (%) 
32 (35.6)  29 (34.5)  0.89 
Patients with one or 
more drug-related 
AEs, n (%) 
14 (15.6)  10 (11.9)  0.49 
  Dizziness  6 (6.6)  5 (6.0)   
  Headache  2 (2.2)  3 (3.6)   
  Facial flushing  3 (3.3)  0   
  Cough 1  (1.1)  0   
  Nausea 1  (1.1)  0   
  Heart burn  1 (1.1)  0   
  Impotence 1  (1.1)  0   
  Skin rash  1 (1.1)  0   
  Fragile fingernail  1 (1.1)  0   
  AST/ALT increase  1 (1.1)  0   
  Skin eruption  0  1 (1.2)   
  Itching 0  1  (1.2)   
  Common cold  0  1 (1.2)   
  Drowsiness 0  1  (1.2)   
  Fatigability 0  2  (2.4)   
LST/HCTZ: losartan/hydrochlorothiazide, AEs: adverse events,
AST: aspartate aminotransferase, ALT: alanine aminotransferase 
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except for one case of liver enzyme increase in the LST/ 
HCTZ group. 
 
Discussion 
 
We have demonstrated that LST 50 mg titrated up 
to a fixed combination of LST/HCTZ 100/25 mg pro-
duced clinically equivalent blood pressure reduction 
to amlodipine besylate 2.5 mg titrated up to 10 mg in 
Korean patients with mild to moderate hypertension. 
Both regimens were comparably well tolerated. 
Previous studies comparing LST with amlodipine in 
Asian populations have reported comparable efficacy 
of the two drugs in reducing blood pressure.
12-17) How-
ever, those studies have generally made an assumption 
that LST 50 mg is equivalent to amlodipine besylate 
5 mg, which is based on the clinical data from Western 
populations.
6-9) In the present study, we adopted a re-
latively conservative strategy for the LST-based regimen, 
assuming that LST 50 mg is equivalent to amlodipine 
besylate 2.5 mg rather than 5 mg, that losartan/HCTZ 
50/12.5 mg is equivalent to amlodipine besylate 5 mg, 
and that losartan/HCTZ 100/25 mg is equivalent to 
amlodipine besylate 10 mg in Korean patients. This strat-
egy is partially supported by the report of Rhew et al., 
in which LST/HCTZ 50/12.5 mg once daily for 12 
weeks did not significantly reduce systolic or diastolic 
blood pressure in Korean patients with ischemic heart 
failure.
18) Adopting this strategy, the patterns and de-
grees of change in SiDBP according to serial time points 
were nearly identical between the two groups, although 
LST 50 mg was more effective than amlodipine besylate 
2.5 mg was in reducing SiSBP. However, it is still uncer-
tain whether Asians, who have been suggested to res-
pond less favorably to angiotensin-converting enzyme 
inhibitors and more favorably to calcium channel block-
ers than Westerners respond less favorably to ARBs. 
In terms of tolerability, the incidence of amlodipine-
related AEs in this study (11.9%) was notably lower 
than that (30%) in a previous summary of 40 placebo-
controlled studies by Osterloh.
18) This difference might 
be attributable to the between-race difference in suscep-
tibility to lower extremity edema, which potentially en-
tails discontinuation of medication.
20) The incidence 
of lower extremity edema in the amlodipine group in 
this study (1.1%) was markedly lower than that (11 to 
24%) seen in previous studies of Westerners.
19-22) In-
deed, only one patient reported lower extremity edema 
in the amlodipine group, which was not considered 
drug-related by the investigator. 
Goldberg et al.
25) reported a placebo-like tolerability 
profile of LST in a previous pooled analysis of 2,900 
patients treated in double-blinded clinical trials. Fixed 
combinations of LST/HCTZ 50/12.5 mg and 100/25 
mg also demonstrated placebo-like tolerability profiles.
26) 
Wu et al.
14) reported better tolerability of LST in an 
Asian population compared with amlodipine in a For-
mosan population. In the present study, the LST-based 
regimen and amlodipine-based regimen showed com-
parable tolerability in terms of the overall incidence of 
AEs (35.6% and 34.5%, respectively) and incidence of 
drug-related AEs (15.6% and 11.9%, respectively). Spe-
cifically, when even 25 mg of hydrochlorothiazide was 
combined with LST in LST/HCTZ 100/25 mg, there 
was no increase in the incidence of AEs, suggesting the 
placebo-like tolerability of this regimen in an Asian po-
pulation. There were no cases of significant uric acid 
elevation or dyslipidemia aggravation. 
In summary, the two regimens, with a relatively hi-
gher dose of LST/HCTZ than that required by Western-
ers, produced equivalent blood pressure reduction and 
were comparably well tolerated in Korean patients with 
mild to moderate hypertension. 
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